Skip to content
Lixivaptan
Lixivaptan is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vasopressin V2 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyponatremiaD007010HP_0002902E87.1——4——4
Autosomal dominant polycystic kidneyD016891EFO_1001496Q61.2—13——4
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I50—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Polycystic kidney diseasesD007690Q61.3————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLIXIVAPTAN
INNlixivaptan
Description
Lixivaptan (VPA-985) is an orally-active, non-peptide, selective vasopressin 2 receptor antagonist being developed as an investigational drug by Palladio Biosciences, Inc. (Palladio), a subsidiary of Centessa Pharmaceuticals plc. As of December 2021, lixivaptan is in Phase III clinical development for the treatment of Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to lixivaptan for the treatment of ADPKD.
Classification
Small molecule
Drug classaptamers, classical and mirror; vasopressin receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc32)c(Cl)c1
Identifiers
PDB—
CAS-ID168079-32-1
RxCUI—
ChEMBL IDCHEMBL49429
ChEBI ID—
PubChem CID172997
DrugBankDB06666
UNII ID8F5X4B082E (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AVPR2
AVPR2
Organism
Homo sapiens
Gene name
AVPR2
Gene synonyms
ADHR, DIR, DIR3, V2R
NCBI Gene ID
554
Protein name
vasopressin V2 receptor
Protein synonyms
Antidiuretic hormone receptor, AVPR V2, Renal-type arginine vasopressin receptor
Uniprot ID
Q9UCV9
Mouse ortholog
Avpr2 (12000)
vasopressin V2 receptor (O88721)
Variants
Clinical Variant
No data
Financial
Lixivaptan - Centessa Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 175 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details